Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

RVNC Revance Therapeutics Inc

3,69

0,42 (12,84%)

18 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Revance Therapeutics Charts.

Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Revance Therapeutics Charts.

News Revance Therapeutics Inc

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Freitag 17 Januar 2025 (19 Stunden vor) • Edgar (US Regulatory)

Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
Donnerstag 16 Januar 2025 (2 Tage vor) • PR Newswire (US)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Montag 13 Januar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Montag 13 Januar 2025 (5 Tage vor) • Edgar (US Regulatory)

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Montag 13 Januar 2025 (5 Tage vor) • PR Newswire (US)

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Montag 13 Januar 2025 (5 Tage vor) • PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 10 Januar 2025 (1 Woche vor) • Edgar (US Regulatory)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
Donnerstag 9 Januar 2025 (1 Woche vor) • PR Newswire (US)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Montag 6 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Montag 6 Januar 2025 (2 Wochen vor) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Donnerstag 2 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Donnerstag 2 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Weitere Revance Therapeutics Inc News-Artikel

Energy Select Sector SPDR

Gold vs US Dollar

Deutsche Lufthansa

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen